Tous Actualités
Suivre
Abonner Groupe Pierre Fabre

Groupe Pierre Fabre

Olivier BOHUON Appointed Chief Executive Officer of Pierre Fabre SA

Castres, France (ots/PRNewswire)

During its first
meeting, the Board of Directors of Pierre Fabre SA chaired by Mr.
Pierre Fabre appointed Olivier BOHUON as the company's Chief
Executive Officer.
Olivier BOHUON, 51, has until now been the executive
vice-president of Abbott Corporation and president of its
pharmaceutics division. In this capacity, he directed the group's
entire pharmaceutical business (22 billion dollars turnover) from
Chicago. He also became group president for Europe in 2003 and
subsequently president of Abbott international.
Olivier BOHUON has also been appointed president of Pierre Fabre
Médicament as of today.
About the Pierre Fabre group
The Pierre Fabre group, owned on a majority basis by a public
utility Foundation, is France's second largest independent
pharmaceutics laboratory and the leader in cosmetics products sold in
pharmacies.
It employs a workforce of nearly 10,000 including 1,400 in
research.
In 2009, the Pierre Fabre group achieved a turnover of 1.8
billion EUR and dedicated 28% of its medical turnover to research and
development in three main therapeutic areas: oncology, central
nervous system, dermatology and cardio-vascular/metabolism.
To find out more about Laboratoires Pierre Fabre :
http://www.pierre-fabre.com

Contact:

CONTACT: Press contacts: Djamila Hazene-Kedjem: +33(0)1-49-10-81-12,
+33(0)6-89-45-87-95,djamila.hazene.kedjem@pierre-fabre.com

Plus de actualités: Groupe Pierre Fabre
Plus de actualités: Groupe Pierre Fabre
  • 02.07.2010 – 11:07

    Olivier Bohuon Joins Pierre Fabre

    Castres, France, July 2, 2010 (ots/PRNewswire) - Olivier Bohuon will be replacing Jean-Pierre Garnier as Chief Executive Officer at Pierre Fabre Group starting September 1, 2010. Until now, Olivier Bohuon, 51, was Executive Vice-President of the Abbott Corporation and President of its pharmaceutical division. As such, he ran the group's entire pharmaceutical activities from Chicago ($22 billion in sales). In 2003, he was named the group's President for European ...